Peroxisome Proliferator-Activated Receptors-Alpha and Gamma Are Targets to Treat Offspring from Maternal Diet-Induced Obesity in Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Magliano, D'Angelo Carlo ^a   Bargut, Thereza Cristina Lonzetti ^a   de Carvalho, Simone Nunes ^a   Aguila, Marcia Barbosa ^a   Mandarim de Lacerda, Carlos Alberto ^a   Souza Mello, Vanessa ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE I; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL COUNT; CELL SIZE; CONTROLLED STUDY; EPIDIDYMIS FAT; FAT MASS; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; IMMUNOBLOTTING; LIVER WEIGHT; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PROGENY; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; WHITE ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; C57BL MOUSE; CALORIC INTAKE; CARBOHYDRATE METABOLISM; COMPLICATION; DRUG SCREENING; ENERGY METABOLISM; GENE EXPRESSION; GENETICS; LIPID DIET; LIVER; MALE; MATERNAL NUTRITION; METABOLISM; PATHOLOGY; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE;

ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; BEZAFIBRATE; BODY WEIGHT; CARBOHYDRATE METABOLISM; CELL SIZE; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; ENERGY INTAKE; ENERGY METABOLISM; FATTY LIVER; FEMALE; GENE EXPRESSION; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; PPAR ALPHA; PPAR GAMMA; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; PRENATAL NUTRITIONAL PHYSIOLOGICAL PHENOMENA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84877877689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064258     Document Type: Article

References (55)

1. Howie GJ, Sloboda DM, Kamal T, Vickers MH, (2009) Maternal nutritional history predicts obesity in adult offspring independent of postnatal diet. J Physiol 587: 905-915.
2. Drake AJ, Reynolds RM, (2010) Impact of maternal obesity on offspring obesity and cardiometabolic disease risk. Reproduction 140: 387-398.
3. Gregorio BM, Souza-Mello V, Carvalho JJ, Mandarim-de-Lacerda CA, Aguila MB, (2010) Maternal high-fat intake predisposes nonalcoholic fatty liver disease in C57BL/6 offspring. Am J Obstet Gynecol 203: 495 e491-498.
4. Gustafson B, Hammarstedt A, Andersson CX, Smith U, (2007) Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 27: 2276-2283.
5. Catta-Preta M, Martins MA, Cunha Brunini TM, Mendes-Ribeiro AC, Mandarim-de-Lacerda CA, et al. (2012) Modulation of cytokines, resistin, and distribution of adipose tissue in C57BL/6 mice by different high-fat diets. Nutrition 28: 212-219.
6. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, et al. (2007) Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116: 39-48.
7. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, et al. (2007) Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 116: 1234-1241.
8. Eckel RH, Grundy SM, Zimmet PZ, (2005) The metabolic syndrome. Lancet 365: 1415-1428.
9. Aguila M, Fernandes-Santos C, Pinheiro-Mulder A, Faria T, Mandarim-de-Lacerda C (2010) Hepatc insulin resistance and nonalcoholic fatty liver disease. In: J M, L G, editors. Insulin resistance: symptons, causes and treatment. New York: Nova Science pu. pp. 1-44.
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR, (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474.
11. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, et al. (2004) Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 5: 27-42.
12. Souza-Mello V, Mandarim-de-Lacerda CA, Aguila MB, (2007) Hepatic structural alteration in adult programmed offspring (severe maternal protein restriction) is aggravated by post-weaning high-fat diet. Br J Nutr 98: 1159-1169.
13. Christodoulides C, Vidal-Puig A, (2010) PPARs and adipocyte function. Mol Cell Endocrinol 318: 61-68.
14. Takahashi S, Tanaka T, Kodama T, Sakai J, (2006) Peroxisome proliferator-activated receptor delta (PPARdelta), a novel target site for drug discovery in metabolic syndrome. Pharmacol Res 53: 501-507.
15. Peters JM, Aoyama T, Burns AM, Gonzalez FJ, (2003) Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta 1632: 80-89.
16. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, et al. (2007) Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 194: 265-271.
17. Tenenbaum A, Fisman EZ, Motro M, Adler Y, (2008) Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 45: 127-153.
18. Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, et al. (2006) Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 536: 182-191.
19. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
20. Barbosa-da-Silva S, Fraulob-Aquino JC, Lopes JR, Mandarim-de-Lacerda CA, Aguila MB, (2012) Weight cycling enhances adipose tissue inflammatory responses in male mice. PLoS One 7: e39837.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
22. Tschanz SA, Burri PH, Weibel ER, (2011) A simple tool for stereological assessment of digital images: the STEPanizer. J Microsc 243: 47-59.
23. Catta-Preta M, Mendonca LS, Fraulob-Aquino J, Aguila MB, Mandarim-de-Lacerda CA, (2011) A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch 459: 477-485.
24. Souza-Mello V, Gregorio BM, Cardoso-de-Lemos FS, de Carvalho L, Aguila MB, et al. (2010) Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet. Clin Sci (Lond) 119: 239-250.
25. Samuelsson AM, Matthews PA, Argenton M, Christie MR, McConnell JM, et al. (2008) Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance: a novel murine model of developmental programming. Hypertension 51: 383-392.
26. Sullivan EL, Smith MS, Grove KL, (2011) Perinatal exposure to high-fat diet programs energy balance, metabolism and behavior in adulthood. Neuroendocrinology 93: 1-8.
27. Fernandes-Santos C, Carneiro RE, de Souza Mendonca L, Aguila MB, Mandarim-de-Lacerda CA, (2009) Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet. Nutrition 25: 818-827.
28. Vickers MH, Reddy S, Ikenasio BA, Breier BH, (2001) Dysregulation of the adipoinsular axis - a mechanism for the pathogenesis of hyperleptinemia and adipogenic diabetes induced by fetal programming. J Endocrinol 170: 323-332.
29. De Souza CT, Frederico MJ, da Luz G, Cintra DE, Ropelle ER, et al. (2010) Acute exercise reduces hepatic glucose production through inhibition of the Foxo1/HNF-4alpha pathway in insulin resistant mice. J Physiol 588: 2239-2253.
30. Teramoto T, Shirai K, Daida H, Yamada N, (2012) Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol 11: 29.
31. Kwon EY, Shin SK, Cho YY, Jung UJ, Kim E, et al. (2012) Time-course microarrays reveal early activation of the immune transcriptome and adipokine dysregulation leads to fibrosis in visceral adipose depots during diet-induced obesity. BMC Genomics 13: 450.
32. Lee JK, Seo EM, Lee SS, Park SH, Sim YB, et al. (2010) Activation of PPARalpha Attenuates IFNgamma and IL-1beta-induced Cell Proliferation in Astrocytes: Involvement of IL-6 Independent Pathway. Korean J Physiol Pharmacol 14: 185-189.
33. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, et al. (2003) Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101: 545-551.
34. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409: 307-312.
35. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, et al. (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101: 1354-1361.
36. Goto T, Lee JY, Teraminami A, Kim YI, Hirai S, et al. (2011) Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes. J Lipid Res 52: 873-884.
37. Berg AH, Combs TP, Scherer PE, (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13: 84-89.
38. Kudoh A, Satoh H, Hirai H, Watanabe T, (2011) Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes. Life sci 88 (23-24):: 1055-62.
39. Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, et al. (2005) Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26: 219-227.
40. Berger Ma, (2002) The mechanisms of action of PPARs. Annu Rev Med 53: 409-435.
41. Rakhshandehroo M, Hooiveld G, Muller M, Kersten S, (2009) Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 4: e6796.
42. Desvergne B, Wahli W, (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20: 649-688.
43. Tenenbaum A, Motro M, Fisman EZ, (2005) Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 4: 14.
44. Lee HJ, Choi SS, Park MK, An YJ, Seo SY, et al. (2002) Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophys Res Commun 296: 293-299.
45. Serviddio G, Giudetti AM, Bellanti F, Priore P, Rollo T, et al. (2011) Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One 6: e24084.
46. Pettinelli P, Videla LA, (2011) Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 96: 1424-1430.
47. Chen G, Liang G, Ou J, Goldstein JL, Brown MS, (2004) Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101: 11245-11250.
48. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF, et al. (2004) A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 279: 36235-36241.
49. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, et al. (2001) The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265.
50. Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, et al. (2003) Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52: 652-657.
51. Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, et al. (2009) Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta 1792: 1080-1086.
52. Brown MS, Goldstein JL, (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89: 331-340.
53. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, et al. (2002) Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem 277: 9520-9528.
54. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, et al. (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278: 34268-34276.
55. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, et al. (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142: 1269-1277.